Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2019-10-20
Target enrollment:
Participant gender:
Summary
This is a Phase 1B study designed to assess the safety and tolerability of LYC-55716 given in
combination with pembrolizumab to subjects with metastatic NSCLC, and to assess the
combination for biologic and clinical activity in NSCLC.